To our knowledge, there is only a phase 1 clinical trial testing a humanized anti-CD40 antibody administered systemically for pediatric central nervous system tumors, including newly diagnosed DIPG (NCT03389802). This evidence concerns the gene CD40 and diffuse intrinsic pontine glioma.